Sanctuary Advisors LLC Decreases Position in Penumbra, Inc. (NYSE:PEN)

Sanctuary Advisors LLC lowered its stake in shares of Penumbra, Inc. (NYSE:PEN) by 29.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,339 shares of the company’s stock after selling 548 shares during the period. Sanctuary Advisors LLC’s holdings in Penumbra were worth $318,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of the stock. True Wealth Design LLC purchased a new position in Penumbra in the 3rd quarter valued at approximately $26,000. UMB Bank n.a. grew its stake in Penumbra by 57.4% in the 4th quarter. UMB Bank n.a. now owns 192 shares of the company’s stock valued at $46,000 after buying an additional 70 shares in the last quarter. Mather Group LLC. grew its stake in Penumbra by 208.0% in the 4th quarter. Mather Group LLC. now owns 308 shares of the company’s stock valued at $73,000 after buying an additional 208 shares in the last quarter. Advisors Asset Management Inc. grew its stake in Penumbra by 11.5% in the 3rd quarter. Advisors Asset Management Inc. now owns 416 shares of the company’s stock valued at $81,000 after buying an additional 43 shares in the last quarter. Finally, GAMMA Investing LLC grew its stake in Penumbra by 160.8% in the 4th quarter. GAMMA Investing LLC now owns 446 shares of the company’s stock valued at $106,000 after buying an additional 275 shares in the last quarter. Hedge funds and other institutional investors own 88.88% of the company’s stock.

Penumbra Stock Performance

NYSE PEN opened at $285.92 on Tuesday. Penumbra, Inc. has a 52-week low of $148.00 and a 52-week high of $310.00. The company has a debt-to-equity ratio of 0.02, a quick ratio of 3.25 and a current ratio of 6.01. The company has a market capitalization of $11.01 billion, a P/E ratio of 840.94, a P/E/G ratio of 2.83 and a beta of 0.53. The company has a fifty day moving average of $264.16 and a 200-day moving average of $233.24.

Penumbra (NYSE:PEN) last posted its quarterly earnings data on Tuesday, February 18th. The company reported $0.97 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.88 by $0.09. Penumbra had a net margin of 1.17% and a return on equity of 9.74%. The company had revenue of $315.52 million during the quarter, compared to the consensus estimate of $311.63 million. As a group, equities research analysts predict that Penumbra, Inc. will post 3.67 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on PEN. Needham & Company LLC reiterated a “hold” rating on shares of Penumbra in a research note on Wednesday, February 19th. BTIG Research lifted their price objective on shares of Penumbra from $232.00 to $270.00 and gave the company a “buy” rating in a research note on Tuesday, November 26th. Royal Bank of Canada lifted their price objective on shares of Penumbra from $285.00 to $313.00 and gave the company an “outperform” rating in a research note on Wednesday, February 19th. Canaccord Genuity Group lifted their price objective on shares of Penumbra from $323.00 to $340.00 and gave the company a “buy” rating in a research note on Wednesday, February 19th. Finally, Wells Fargo & Company boosted their price target on shares of Penumbra from $275.00 to $305.00 and gave the company an “overweight” rating in a research report on Wednesday, February 19th. Four investment analysts have rated the stock with a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Penumbra currently has a consensus rating of “Moderate Buy” and an average price target of $292.64.

Insider Transactions at Penumbra

In other Penumbra news, Director Harpreet Grewal sold 167 shares of the business’s stock in a transaction on Friday, January 3rd. The shares were sold at an average price of $241.28, for a total value of $40,293.76. Following the completion of the sale, the director now directly owns 8,530 shares of the company’s stock, valued at $2,058,118.40. The trade was a 1.92 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Adam Elsesser sold 15,000 shares of the business’s stock in a transaction on Friday, December 20th. The stock was sold at an average price of $242.96, for a total transaction of $3,644,400.00. Following the completion of the sale, the chief executive officer now directly owns 837,582 shares of the company’s stock, valued at $203,498,922.72. This represents a 1.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.00% of the stock is currently owned by insiders.

Penumbra Profile

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.